Skip to content

Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity

Randomized Controlled Trial Investigating the Effects of a Standardized Aerobic Exercise Intervention on Cognitive Function and Brain Connectivity in Relapsing-remitting Multiple Sclerosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02005237
Acronym
AERCONN
Enrollment
68
Registered
2013-12-09
Start date
2013-12-31
Completion date
2016-11-30
Last updated
2017-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Exercise, Cognition, Neuroimaging, Rehabilitation, Connectivity

Brief summary

Cognitive dysfunction is frequent in patients with multiple sclerosis (MS) and to date, there are no available treatments to improve cognition in this patient population. Some evidence from animal studies and small clinical trials suggest that aerobic exercise might beneficially affect cognitive function in MS. The aim of this randomized-controlled trial is to explore if an aerobic exercise training program can enhance cognition in MS. In addition, we will employ neuroimaging markers to determine if exercise alters measures of brain structure and function. Patients will be randomly assigned to either a 3-months exercise program (bicycle ergometry, 2-3 session per week) or a waitlist control group. The primary endpoint of the study is a test of verbal learning and memory. Secondary endpoints include neuroimaging markers of functional and structural connectivity in the brain. We hypothesize that exercise will improve verbal learning and memory and beneficially affect measures of brain connectivity.

Detailed description

Background: Cognitive dysfunction is frequent in patients with multiple sclerosis (MS) and to date, there are no available treatments to improve cognition in this patient population. Some evidence from animal studies and small clinical trials suggest that aerobic exercise might beneficially affect cognitive function in MS. Aims: This study aims to explore the potential of an aerobic exercise program on brain structure and function in MS in a single-blind, randomized controlled phase IIa trial. We hypothesize that exercise will improve verbal learning and memory (primary endpoint) as well as induce changes in neuroimaging markers of structural and functional central nervous system (CNS) connectivity (secondary endpoints). Tertiary outcomes will include walking ability, motor function and coordination, as well as patient-based outcomes (depression, fatigue, and health-related quality of life). Design: This is a single-blind, randomized, controlled phase IIa trial with a parallel group design comparing 3 months of standardized aerobic exercise training (bicycle ergometry) to a waitlist control group (superiority framework). The allocation ratio of exercise to waitlist control is 1:1 with a sample size of n=60.

Interventions

BEHAVIORALAerobic Exercise

3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity

Sponsors

German Federal Ministry of Education and Research
CollaboratorOTHER_GOV
Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Relapsing-remitting multiple sclerosis according to McDonald criteria * Currently in remission * Disease duration \< 10 years * Low to moderate physical disability (EDSS 0-3.5) * On stable immunotherapy (\>3 months) or without any planned treatment for the next year

Exclusion criteria

* Patients who are not able to understand the study concept due to severe cognitive deficits or psychiatric comorbidity * Patients currently taking psychoactive drugs * Patients unable to undergo aerobic exercise training for medical reasons * Patients with active disease or uncertain stability under current immunomodulatory therapy (as judged by the treating neurologist) * Patients with implants or body modifications (e.g. dental implants, piercings, tattoos, pacemakers etc.) which might interfere with MEG and MRI assessments * Patients unable to travel to the study center 2-3 times a week for the duration of the study

Design outcomes

Primary

MeasureTime frameDescription
Change in Verbal Learning and MemoryBaseline and at Month 3 (end of intervention)Verbal Learning and Memory will be assessed with the Verbal Learning and Memory Test (VLMT)

Secondary

MeasureTime frameDescription
Change in Functional ConnectivityBaseline and at Month 3 (end of intervention)Functional connectivity of CNS networks will be assessed by resting-state functional magnetic resonance imaging (rs fMRI) and resting-state magnetoencephalography (rs MEG)
Change in Structural ConnectivityBaseline and at Month 3 (end of intervention)Structural connectivity and integrity of CNS networks will be assessed by diffusion tensor imaging (DTI) as well as measures of gray matter density using magnetic resonance imaging (MRI)
Change in Neuropsychological FunctionBaseline and at Month 3 (end of intervention)Neuropsychological function will be assessed using a standardized battery covering the following domains: visuospatial learning and memory, attention, processing speed, working memory, and social cognition

Other

MeasureTime frameDescription
Change in Patient-Reported OutcomesBaseline and at Month 3 (end of intervention)Patient-reported outcomes will be assessed for depressive symptoms (IDS-30SR), fatigue (FSMC), quality of life (HAQUAMS), and walking (MSWS-12)
Change in Walking AbilityBaseline and at Month 3 (end of intervention)Walking ability will be assessed using the six-minute-walk test (6MWT) as well as Actibelt accelerometry

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026